Past Podcast Episodes

MS can limit your ability to get around and do the things you like to do. And when that happens, the right mobility device can be a game-changer when it comes to staying safe, staying active, and improving your quality of life.

This week, Dr. Evan Cohen joins me to discuss how to know when it's time to consider a mobility device, and how to choose the right mobility device for you.

We're also presenting findings from two separate studies that shed significant light on how the gut microbiome interacts with the brain and how its composition varies among individuals with MS.

We'll tell you what happened when a research team gave a multiple-choice “test” measuring MS expertise to neurologists and neurology residents and then gave the same test to the leading artificial intelligence platforms.

And we'll share an opportunity for you to participate in MS research by taking the PROMS Initiative's eHealth survey.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Choosing the right mobility device  :22

Differences in the gut microbiome of people with MS  1:28

Evidence shows the vagus nerve is the connection between the gut and the brain  3:53

Who won the “MS expertise” showdown between neurologists and AI?  6:18

Your opportunity to participate in MS research by taking the PROMS Initiative eHealth survey  8:31

Dr. Evan Cohen shares everything you need to know about choosing a mobility device  10:27

Share this episode  30:57

Have you downloaded the free RealTalk MS app?  31:15

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/391

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

RealTalk MS on YouTube
https://www.youtube.com/@RealTalkMS

STUDY: Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients with Multiple Sclerosis
https://neurology.org/doi/10.1212/NXI.0000000000200355

STUDY: Select Microbial Metabolites In the Small Intestinal Lumen Regulates Vagal Activity Via Receptor-Mediated Signaling
https://cell.com/iscience/fulltext/S2589-0042(24)02926-2

STUDY: Artificial Intelligence Versus Neurologists: A Comparative Study on Multiple Sclerosis Expertise
https://sciencedirect.com/science/article/abs/pii/S030384672500068X

RESEARCH PARTICIPATION OPPORTUNITY: The Global PROMS Initiative eHealth Survey
https://proms-initiative.org

Join the RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

Download the RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200

Download the RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk

Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on X @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 391
Guest: Dr. Evan Cohen

This special episode of RealTalk MS is sponsored by Sanofi.  By now, you may have come across the term smoldering MS and wondered what it means. An international panel of MS experts has published a consensus statement on the definition, biology, and clinical implications of smoldering MS. Joining me is the lead author of that paper, Dr. Antonio Scalfari.

Dr. Antonio Scalfari has a research background in multiple sclerosis and neuro-inflammatory conditions. Along with other consultants, he manages the multiple sclerosis and neuro-inflammatory diseases service at Charing Cross and St Mary's hospitals and is a general neurologist at London North West Healthcare NHS Trust.

Sanofi convened the meetings and paid for medical writing assistance, but the authors worked independently to develop and draft the consensus statement. While Dr. Scalfari has been compensated by Sanofi, his views and opinions are his own and do not necessarily reflect those of Sanofi.